- In March 2023, Oxford Immunotec announced U.S. FDA clearance for its enhanced T-Cell Select Kit, enabling optimized sample preparation and extended usability of its T-SPOT.TB test. This regulatory milestone facilitates broader clinical application of FluoroSpot-based T-cell measurement tools, further cementing Oxford Immunotec’s leadership in tuberculosis and immune monitoring diagnostics. The upgraded kit enhances workflow efficiency and stability, supporting expanded use in both hospital and reference laboratory settings
- In September 2023, Virax Biolabs launched the ViraxImmune FluoroSpot-based SARS-CoV-2 T-cell assay, targeting evaluation of immune response to COVID-19. This innovative solution enables detection of T-cell reactivity in previously infected or vaccinated individuals, offering valuable insight for long-term immunity studies. The launch reinforces Virax Biolabs' role in advancing cellular immunity testing during and beyond the pandemic era
- In 2024, Mabtech AB introduced a new generation of triple-color FluoroSpot kits, allowing for the simultaneous detection of multiple cytokines such as IFN-γ, IL-2, and IL-17. This multiplex format offers improved sensitivity and broader application in vaccine development, autoimmune disease research, and infectious disease studies. The kits have been widely adopted across immunology labs due to their high accuracy and reduced assay time
- In April 2024, Cellular Technology Limited (CTL) launched an AI-powered FluoroSpot reader, aimed at enhancing data analysis speed and consistency. The upgraded platform leverages machine learning for automated spot counting and classification, significantly reducing operator-dependent variability and boosting throughput in clinical trial environments and academic research labs
- In 2024, Abcam released a series of ready-to-use ELISpot and FluoroSpot assay kits, designed for easier implementation in resource-constrained labs. These kits feature pre-coated plates and optimized buffers, simplifying the workflow and reducing error rates. With rapid adoption in small- to mid-sized research institutions, the kits have contributed to democratizing access to high-sensitivity T-cell analysis technologies
